Recall of 2 batches of Anzatax Injection Concentrate 300mg/50ml

Hospira Singapore, in consultation with the Health Sciences Authority (HSA), is conducting a voluntary recall of 2 batches of Anzatax Injection Concentrate 300mg/50ml due to possible quality concerns associated with these batches. Hospira has received a limited number of customer complaints worldwide (outside Singapore) for visual vial defects which resembled a rust-like mark at the neck of the vial or black particles close to the neck of the vials that were used in the manufacture of certain batches of Anzatax Injection Concentrate 300mg/50ml. Healthcare professionals should stop using the affected batches of the Anzatax Injection Concentrate and are advised to visually inspect the Anzatax Injection Concentrate before administering the medicinal product. Please refer to the letter for further information.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.